Accelerate to discover

Back to filter

Related topics

Low-dose imaging in a new preclinical total-body PET/CT scanner

Bruker Biospin

Jun 12, 2019

Ionizing radiation constitutes a health risk to imaging scientists and study animals. Both PET and CT produce ionizing...

Fluxion Biosciences and National Cancer Institute cooperate to validate IsoFlux for sequencing

Fluxion Biosciences

Jun 12, 2019

Fluxion with IsoFlux has partnered with the Cleveland Clinic. They are aiming to improve sensitivity by timing the...

New insight into Cas9 off-target activity

LUMICKS

Jun 7, 2019

Scientists at the MRC London Institute of Medical Sciences and AstraZeneca studied how CRISPR-Cas9 differentiates...

Join the AVANCE Track & Keep your MRI on Track

Bruker Biospin

Jun 4, 2019

Your research depends on the scientific advances that you make with your MRI instrument. Take your instrument and your...

Jun 18, 2019

A novel method for isolating high-quality UHMW DNA from animal and human tissues

BioNano Genomics

May 31, 2019

New isolation protocol for isolating high-quality UHMW DNA from 10 mg of freshly frozen or liquid-preserved animal and...

ParaVision 7 software

Bruker Biospin

May 27, 2019

The preclinical MRI software ParaVision 7 delivers unsurpassed image quality and enhanced productivity for both routine...

HLS-CATCH: Cas-9 assisted gene purification

Sage Science

May 24, 2019

The CATCH process  provides researchers with the most direct access to genes for study. Target regions are defined with...

Jun 18, 2019

Introducing the first EV isolation column capable of running 100 mL samples.

IZON

May 21, 2019

As the EV field continues to grow and advance, so has the need for scalability in EV isolation. Izon is addressing this...

Show all topics (10)

Better antibody discovery using IntelliCyt’s iQue Screener

May 18, 2016

With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.

Read more

 

Scientific paper
Product news

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

IntelliCyt

IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey